GLP-1 and Endometriosis: Do Ozempic and Mounjaro Really Reduce Inflammation and Endobelly?

Before we dive into this topic, a quick and important reminder: The content shared on the EndoMe blog is for educational and informational purposes only. It does not replace consultation with a specialist and does not constitute a recommendation to use medications outside of their approved indications.

If you've recently fallen down the internet rabbit hole of "weight loss" medications that supposedly "treat endometriosis," you're not alone. The topic of Ozempic, Mounjaro, and Wegovy in the context of endometriosis has exploded on TikTok and Instagram with such force that more and more women are asking themselves the question, "Will this help my condition?" Support groups are flooded with testimonials from patients who, after a few weeks on semaglutide or tirzepatide, describe not only weight loss but also less bloating, lighter periods, and a noticeably calmer experience. stomach.

This wave of enthusiasm naturally raises the question: Can these drugs actually help with endometriosis? Is this just another "miracle therapy" that will prove to be a disappointment in a year? Let's try to calmly dissect this topic, because it deserves more than headlines like "scientists discover cure for endometriosis."

What exactly are GLP-1 drugs?

GLP-1, or glucagon-like peptide type 1, is a hormone naturally produced in the intestines after a meal. It regulates insulin secretion, slows gastric emptying, and influences the satiety center in the brain. Drugs in this group, known as GLP-1 analogs, mimic the effects of this hormone in a much more potent and longer-lasting way than the natural version.

The most well-known medications are semaglutide, sold in Poland under the names Ozempic (registered for the treatment of type 2 diabetes) and Wegovy (registered for the treatment of obesity), and tirzepatide, known as Mounjaro, which acts simultaneously on GLP-1 and GIP receptors. All of these medications were originally developed for patients with diabetes and obesity. Their emergence in pop culture as "celebrity weight loss drugs" is a side effect of their real effectiveness in weight loss and metabolic regulation.

None of these preparations are currently registered as medications for endometriosis. Any use of these products by women with endometriosis is considered off-label, meaning use outside of the labeled indications is the sole responsibility of the treating physician.

What theorizes the link between GLP-1 and endometriosis

Despite the lack of approval, there are several strong, biologically sound reasons why scientists have begun to look at this group of drugs in the context of endometriosis.

Firstly, endometriosis It is an inflammatory disease with a systemic basis. It is not limited to the pelvic floor but affects the entire body, including the gut microbiota, estrogen metabolism, and the level of chronic low-grade inflammation. GLP-1 receptors are found not only in the pancreas and intestines, but also in the brain, heart, and adipose tissue. A growing body of research shows that GLP-1 agonists have anti-inflammatory effects, lowering the levels of proinflammatory cytokines such as TNF-alpha, IL-6, and CRP. Theoretically, they could affect the inflammatory background that drives symptoms endometriosis.

Secondly, a significant proportion of women with endometriosis exhibit insulin resistance or elements thereof, even if they are slim. Insulin resistance and hyperinsulinemia drive inflammation, promote estrogen overproduction in adipose tissue, and exacerbate hormonal imbalances. GLP-1 medications improve insulin sensitivity, which can significantly reduce hormone-dependent symptoms in patients with this profile.

Third, adipose tissue, especially visceral fat, is an active endocrine organ that produces estrogen from androgens through aromatization. In women with excess adipose tissue, this translates into higher systemic estrogen levels, which fuel endometriosis lesions. The weight loss observed with GLP-1 treatment may therefore indirectly reduce the estrogenic "feeding" of the disease.

Fourth, the effects of these medications on the digestive system. Slowing gastric emptying and changes in intestinal motility translate into less bloating, less gas, and slower, more orderly intestinal transit in many patients. This may subjectively reduce the so-called endo-belly, the characteristic, rapid abdominal distention that accompanies endometriosis. However, it is important to understand that this is not a cure-all. leczenie endo-belly at the source, only a side effect that helps some, but may aggravate intestinal problems in others.

What does scientific research say?

And here comes the biggest "but." Direct clinical trials on the use of semaglutide or tirzepatide in endometriosis are currently few and mainly survey preclinical, in animal or cell models, or very small observations.

In 2023 and 2024, studies appeared suggesting that GLP-1 agonists could inhibit endometrial cell proliferation in the laboratory and reduce the vascularization and volume of endometriosis lesions in mice. These are promising results, but they are a long way from concluding that "GLP-1 treats endometriosis in women." Before such a recommendation could appear in ESHRE or PTGiP guidelines, multicenter, randomized clinical trials in humans are needed, and these are not yet completed.

Patients' reports of improved well-being are real and shouldn't be dismissed. However, it's important to remember that observations like "I started Ozempic and my stomach hurts less" may result from multiple mechanisms simultaneously. These include weight loss, dietary changes (these medications naturally suppress appetite, so women eat less and often differently), improved blood sugar levels, anti-inflammatory effects, and the placebo effect, which can be very strong in chronic conditions. We don't yet know which of these mechanisms accounts for which portion of the improvement.

Side effects and real risks worth knowing about

GLP-1 medications are not an innocent supplement. They are associated with specific side effects that are worth being aware of, especially if you're considering discussing this with your doctor.

The most common side effects include nausea, vomiting, diarrhea or, conversely, constipation, abdominal pain, reflux, and a feeling of fullness. For women with intestinal endometriosis, who already have a sensitive digestive system, these symptoms may initially worsen their well-being. Some patients also report an increase in endometriosis in the first few weeks of therapy, before their bodies adjust.

More serious, though rarer, risks include pancreatitis, gallstones (the risk increases with rapid weight loss), gastric motility disorders, and, in very rare cases, the risk of thyroid cancer. The latter is an absolute contraindication in individuals with a personal or family history of medullary thyroid cancer. These drugs are also contraindicated in pregnancy and when planning a pregnancy. The manufacturer recommends discontinuing semaglutide at least two months before trying to conceive, and tirzepatide appropriately earlier. This is important information for women with endometriosis who combine symptomatic treatment with plans for childbirth.

Availability is a separate issue. Ozempic and Mounjaro are reimbursed in Poland only for type 2 diabetes. Using them "on endo" requires full reimbursement, with monthly costs ranging from several hundred to over a thousand złoty. This is a real barrier that shouldn't be ignored.

Is it worth talking to a doctor about this?

The short answer is yes, but with the right doctor and in the right context. An endocrinologist, diabetologist, or a good gynecologist specializing in endometriosis can assess whether, in your specific case, GLP-1 therapy could provide benefits that outweigh the risks.

Real candidates for such a discussion are women with endometriosis who also have insulin resistance, obesity, polycystic ovary syndrome (PCOS), or type 2 diabetes. In these situations, the drug would fulfill its approved function, and the potential benefits for endometriosis would be a welcome additional benefit. However, a slim woman with endometriosis without metabolic disorders is not currently a good candidate for off-label use of GLP-1 solely for "endo treatment." We simply do not have the data to support this, and the risk of side effects remains.

Before making any decisions, it's worth performing basic diagnostics. Fasting glucose and insulin with HOMA-IR calculation, lipid profile, TSH, liver and kidney function tests, and if planning a pregnancy, a full gynecological consultation. Decisions regarding this group of medications shouldn't be made based on social media posts or a friend's report.

What you can do regardless of your GLP-1 decision

The mechanisms that explain GLP-1's potential effectiveness in endometriosis—reducing inflammation, improving insulin sensitivity, regulating the microbiota, and reducing peripheral estrogen—can largely be supported by daily habits. This doesn't replace treatment, but it forms its foundation.

Diet Low-glycemic diets based on vegetables, good fats, whole-grain carbohydrate sources, and sufficient protein target the same metabolic pathways as GLP-1, only more gently. Regular moderate-intensity exercise, especially strength training, improves insulin sensitivity more than most pharmacological interventions. Sleeping less than seven hours increases insulin resistance overnight. Nurturing the gut microbiota through a diet rich in fiber, fermented foods, and probiotics affects both inflammation and estrogen metabolism in the gut, in the so-called estrobolome.

These are not spectacular interventions, but they are the foundation on which any additional therapy, pharmacological or not, works better.

Summary, or what to stick to

GLP-1 drugs, such as Ozempic and Mounjaro, are a promising avenue of research in the context of endometriosis, but they currently do not offer a cure for the disease. They have anti-inflammatory and metabolic effects that could theoretically support women with endometriosis, especially those with concomitant insulin resistance or obesity. However, there are no large clinical trials that would allow for the formulation of clear recommendations.

If you're considering this therapy, talk to a doctor who knows your history and your results, not online. If you decide to pursue it, consider GLP-1 as one component of a larger plan in which diet, exercise, sleep, mental health, and proper endometriosis management are all equally important. And if this option eludes you for various reasons, remember that you have many tools at your disposal that work on the same mechanisms. They just require a little more patience.

Źródła:

1. Drucker DJ, "The benefits of GLP-1 drugs beyond obesity", Science, 2024.
2. Bryant-Smith AC et al., “Emerging pharmacological targets for endometriosis: from molecular mechanisms to clinical trials,” Human Reproduction Update, 2023.
3. ESHRE Guideline "Endometriosis", European Society of Human Reproduction and Embryology, 2022.
4. Summary of Product Characteristics for Ozempic (semaglutide) and Mounjaro (tirzepatide), current versions available on the EMA and URPL websites.
5. Marchandot B. et al., "GLP-1 receptor agonists and cardiovascular and metabolic outcomes: pleiotropic effects beyond glycemic control", Cardiovascular Diabetology, 2023.